112 related articles for article (PubMed ID: 33866281)
1. CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
Fan Z; Zheng D; Wen X; Shen F; Lei L; Su S; Zhang S; Liu Q; Zhang X; Lu Y; Di L; Shen XM; Da Y
J Neuroimmunol; 2021 Jun; 355():577571. PubMed ID: 33866281
[TBL] [Abstract][Full Text] [Related]
2. Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.
Chen D; Hou S; Zhao M; Sun X; Zhang H; Yang L
Eur J Neurol; 2018 Aug; 25(8):1049-e80. PubMed ID: 29611886
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
4. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study.
Liu J; Guo YP; Jiao Z; Zhao CB; Wu H; Li ZR; Cai XJ; Xi JY
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):453-466. PubMed ID: 32170643
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus treatment in childhood refractory nephrotic syndrome: A retrospective study on efficacy, therapeutic drug monitoring, and contributing factors to variable blood tacrolimus levels.
Guo HL; Xu J; Sun JY; Li L; Guo HL; Jing X; Xu ZY; Hu YH; Xu ZJ; Sun F; Ding XS; Chen F; Zhao F
Int Immunopharmacol; 2020 Apr; 81():106290. PubMed ID: 32058933
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
11. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
13. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
[TBL] [Abstract][Full Text] [Related]
14. Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.
Meng HY; Li X; Jin WL; Yan CK; Dong XH; Xu Q; Peng YY; Li ZB; Li Y; Luo ZH; Xu LQ; Yang H
Eur J Clin Pharmacol; 2020 May; 76(5):659-671. PubMed ID: 31955224
[TBL] [Abstract][Full Text] [Related]
15. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
17. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
18. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients.
Déri M; Szakál-Tóth Z; Fekete F; Mangó K; Incze E; Minus A; Merkely B; Sax B; Monostory K
Sci Rep; 2021 Nov; 11(1):21389. PubMed ID: 34725418
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
20. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Habuchi T; Satoh S; Miura M
Int J Mol Sci; 2015 Jan; 16(1):1840-54. PubMed ID: 25594874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]